SEHK:9969Biotechs
InnoCare Pharma (SEHK:9969) Stock May Be Fully Priced Despite 129% Returns
InnoCare Pharma has delivered a strong 3 year share price gain, yet current valuation checks flag the stock as overvalued on market multiples and the broader picture looks mixed rather than clearly cheap.
Over the past 3 years, InnoCare Pharma shares returned 129.3%, which raises the question of how much of the future story is already reflected in the price.
New clinical trial approval for the bispecific ADC ICP-B381 may support sentiment around the oncology pipeline, while execution risk...